莫沙必利联合雷贝拉唑治疗老年性反流性食管炎的效果及对血浆胃肠激素和血清细胞因子的影响  

Mosapride Combined with Rabeprazole in the Treatment of Senile Reflux Esophagitis and Its Effect on Plasma Gastrointestinal Hormones and Serum Cytokines

作　　者：张金光 ZHANG Jinguang(Department of Gastroenterology,People's Hospital of Yutai County,Yutai,Shandong Province,272300 China)

机构地区：[1]山东省鱼台县人民医院消化内科,山东鱼台272300

出　　处：《系统医学》2022年第1期93-96,共4页Systems Medicine

摘　　要：目的探讨对老年性反流性食管炎采用莫沙必利联合雷贝拉唑治疗的临床效果及对改善患者血浆胃肠激素和血清细胞因子水平的作用。方法选择该院2020年1—12月收治的老年性反流性食管炎患者90例,按照随机数表法分组,分为单用雷贝拉唑治疗对照组(n=45)与雷贝拉唑联合莫沙必利治疗研究组(n=45),比较两组临床疗效,检测治疗前后两组胃肠激素血管活性肠肽(VIP)、胃动素(MTL)、胃泌素(GAS)水平,比较血浆胃肠激素变化,并检测血清白介素(IL)-6、IL-8、肿瘤坏死因子(TNF)-α水平,比较血清细胞因子变化,随访6个月比较两组复发率。结果研究组治疗总有效率93.33%,高于对照组77.78%;随访6个月复发率17.78%,低于对照组37.78%,差异有统计学意义(χ^(2)=4.406、4.486,P<0.05)。治疗后研究组VIP水平为(17.34±4.10)pg/mL,低于对照组;MTL、GAS水平分别为(320.85±45.04)、(160.59±19.48)pg/mL,高于对照组;血清IL-6、IL-8、TNF-α水平分别为(9.54±2.15)、(13.61±3.13)、(9.16±1.55)pg/mL,均低于对照组,差异有统计学意义(t=3.288、3.587、7.385、10.434、7.479、9.066,P<0.05)。结论对老年性反流性食管炎患者在雷贝拉唑治疗的基础上联用莫沙必利可提高临床疗效,能够改善胃肠激素分泌状态,且可减轻机体炎性反应,有利于控制复发率,值得推广。Objective To investigate the clinical effect of mosapride combined with rabeprazole in the treatment of senile reflux esophagitis and its effect on improving the levels of plasma gastrointestinal hormones and serum cytokines in patients.Methods A hospital was selected to treat 90 patients with senile reflux esophagitis from January to December 2020,and they were grouped according to the random number table method.Divided them into a single rabeprazole treatment control group(n=45)and rabeprazole combined with mosapride treatment study group(n=45).The clinical efficacy of the two groups was compared,and the levels of gastrointestinal hormones vasoactive intestinal peptide(VIP),motilin(MTL)and gastrin(GAS)were detected before and after treatment to compare the changes of plasma gastrointestinal hormones.The levels of serum interleukin(IL)-6,IL-8,and tumor necrosis factor(TNF)-αwere also tested to compare the changes of serum cytokines.The recurrence rates of the two groups were compared after 6 months of follow-up.Results The total effective rate of treatment in the study group was 93.33%,which was higher than 77.78%in the control group,the recurrence rate was 17.78%in the 6-month follow-up,which was lower than 37.78%in the control group,and the difference was statistically significant(χ^(2)=4.406,4.486,P<0.05).After treatment,the VIP level of the study group was(17.34±4.10)pg/mL,which was lower than that of the control group.The levels of MTL and GAS were(320.85±45.04)pg/mL and(160.59±19.48)pg/mL,respectively,which were higher than those of the control group,serum IL-6,IL-8,and TNF-αlevels were(9.54±2.15)pg/mL,(13.61±3.13)pg/mL,(9.16±1.55)pg/mL,respectively,which were all lower than those of the control group,the difference was statistically significant(t=3.288,3.587,7.385,10.434,7.479,9.066,P<0.05).Conclusion For patients with senile reflux esophagitis,rabeprazole combined with mosapride can improve the clinical efficacy and improve the secretion of gastrointestinal hormones.And it can reduce the body's

关 键 词：老年性反流性食管炎 莫沙必利 雷贝拉唑 血浆胃肠激素 血清细胞因子 复发率 

分 类 号：R4[医药卫生—临床医学]